I. MODIFIED AGREEMENTS | |||
Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
JUNE | |||
Prosensa BV* (the Netherlands) | GlaxoSmithKline plc (UK) | Initiated two further programs under their alliance covering RNA-based treatments for Duchenne's muscular dystrophy | GSK made two initiation payments to Prosensa, which is now eligible for further pre-option milestone payments based on research progress (6/24) |
II. TERMINATED AGREEMENTS | |||
Exelixis Inc. (EXEL) | Bristol-Myers Squibb Co. | Terminated deal to develop XL184, a small-molecule MET inhibitor | Exelixis regained full rights after the firms could not agree on the scope, breadth and pace of the ongoing clinical development; BMS is paying $17M in connection with the return (6/22) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
The date indicated refers to the BioWorld Today issue in which the news item can be found. | |||
* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. |